Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
EGF816 for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial is a Phase I/II study, which means it is testing a new drug to see if it is safe and effective. The first part (Phase I) is a dose-escalation phase, which is designed to find the maximum tolerated dose (MTD) or recommended Phase II dose (RP2D) of the drug. The second part (Phase II) is an expansion phase, which is designed to estimate the antitumor activity of the drug.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.